6d
Medpage Today on MSNSurvival Win for Pembrolizumab in Early Triple-Negative Breast CancerPD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
MedPage Today on MSN7d
Another Possible Treatment Option for Intermediate-Stage Liver CancerMedian PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results